- Compass Pathways plc CMPS has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression.
- The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with rapid and durable treatment response.
- The 10mg vs. 1mg dose did not show a statistically significant difference at week 3.
- At least twice the number of patients in the 25mg group showed a response and remission at week 3 and week 12, compared with the 1mg group.
- COMP360 was generally well tolerated, with more than 90% of treatment-emergent adverse events being mild or moderate in severity.
- The Company plans to start a pivotal phase 3 program in 2022.
- Compass posted a Q3 EPS loss of $(0.38) higher than $(1.30) a year ago.
- Cash and cash equivalents were $294.0 million.
- Price Action: CMPS shares up 7.78% at $39.71 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechCannabisEarningsNewsHealth CareSmall CapMarketsMoversTrading IdeasGeneraldepressionPhase 2 TrialPsychedelics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.